Abstract 2620
Background
Absenteeism and presenteeism (A/P) are scales related to health problems and professional activity in patients and in healthy individuals. For cancer patients in the age of maximum labor productivity (18 to 65 years old), A/P are possibly affected by quality of care, type of cancer, and selection of treatments. The objectives of this study were to clarify via questionnaire the association between quality-of-life (QOL) and A/P, as well as the changes of A/P during clinical course in cancer patients.
Methods
A/P were measured using the validated Japanese version of the World Health Organization Health and Work Performance Questionnaire (WHO-HPQ). QOL was measured using the 5-level EQ-5D version via a portable device with the Apple ResearchKit app.
Results
We received 3983 survey results (healthy individuals, 297; cancer patients, 3686). Presenteeism was clearly different between cancer patients and healthy individuals (absolute/relative presenteeism: 59.3/0.93 and 65.8/1.01, respectively). Examination of the relationship between QOL and A/P using Spearman’s rank correlation coefficient analysis indicated that QOL is significantly correlated with relative presenteeism (r = 0.40, P < 0.001). The labor performance of pancreatic carcinoma patients was low (absolute/relative absenteeism: 68.7/0.29, absolute/relative presenteeism: 43.8/0.68). The A/P in patients with receiving chemotherapy were not maintained compared to in patients receiving surgical treatment (absolute/relative absenteeism: 39/8/0.16 vs. 17.8/0.02, p = 0.04, absolute/relative presenteeism: 55.5/0.83 vs. 62.8/0.95, p < 0.001, respectively).
Conclusions
WHO-HPQ can be used to measure the labor performance in cancer patients. Moreover, A/P was strongly affected by type of cancers and selection of treatments.
Clinical trial identification
Editorial acknowledgement
The research was supported by Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Legal entity responsible for the study
Shunsuke Kondo.
Funding
Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract